231 related articles for article (PubMed ID: 29544689)
1. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer.
Atherton MJ; Stephenson KB; Nikota JK; Hu QN; Nguyen A; Wan Y; Lichty BD
Vaccine; 2018 Apr; 36(16):2181-2192. PubMed ID: 29544689
[TBL] [Abstract][Full Text] [Related]
2. Customized Viral Immunotherapy for HPV-Associated Cancer.
Atherton MJ; Stephenson KB; Pol J; Wang F; Lefebvre C; Stojdl DF; Nikota JK; Dvorkin-Gheva A; Nguyen A; Chen L; Johnson-Obaseki S; Villeneuve PJ; Diallo JS; Dimitroulakos J; Wan Y; Lichty BD
Cancer Immunol Res; 2017 Oct; 5(10):847-859. PubMed ID: 28912369
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses.
Woodham AW; Cheloha RW; Ling J; Rashidian M; Kolifrath SC; Mesyngier M; Duarte JN; Bader JM; Skeate JG; Da Silva DM; Kast WM; Ploegh HL
Cancer Immunol Res; 2018 Jul; 6(7):870-880. PubMed ID: 29792298
[TBL] [Abstract][Full Text] [Related]
4. Considerations for Clinical Translation of MG1 Maraba Virus.
Breitbach CJ
Methods Mol Biol; 2020; 2058():285-293. PubMed ID: 31486046
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB; Lichty BD; Auer RC; Stojdl DF; Bell JC; Bourgeois-Daigneault MC
Nat Commun; 2021 May; 12(1):2626. PubMed ID: 33976179
[TBL] [Abstract][Full Text] [Related]
6. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
Bourgeois-Daigneault MC; St-Germain LE; Roy DG; Pelin A; Aitken AS; Arulanandam R; Falls T; Garcia V; Diallo JS; Bell JC
Breast Cancer Res; 2016 Aug; 18(1):83. PubMed ID: 27503504
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
[TBL] [Abstract][Full Text] [Related]
8. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
9. Maraba virus as a potent oncolytic vaccine vector.
Pol JG; Zhang L; Bridle BW; Stephenson KB; Rességuier J; Hanson S; Chen L; Kazdhan N; Bramson JL; Stojdl DF; Wan Y; Lichty BD
Mol Ther; 2014 Feb; 22(2):420-429. PubMed ID: 24322333
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy with two attenuated Listeria strains carrying shuffled HPV-16 E6E7 protein causes tumor regression in a mouse tumor model.
Su L; Zhang Y; Zhang X; Liu T; Liu S; Li Y; Jiang M; Tang T; Shen H; Wang C
Sci Rep; 2021 Jun; 11(1):13404. PubMed ID: 34183739
[TBL] [Abstract][Full Text] [Related]
11. Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.
Varypataki EM; Benne N; Bouwstra J; Jiskoot W; Ossendorp F
Cancer Immunol Res; 2017 Mar; 5(3):222-233. PubMed ID: 28143806
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene.
Gao J; Fan L; Ma W; Xiao H
Microbiol Immunol; 2016 Sep; 60(9):626-33. PubMed ID: 27515281
[TBL] [Abstract][Full Text] [Related]
13. Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.
Pol JG; Bridle BW; Lichty BD
Methods Mol Biol; 2020; 2058():191-211. PubMed ID: 31486039
[TBL] [Abstract][Full Text] [Related]
14. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
15. Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine.
de Oliveira LM; Morale MG; Chaves AA; Cavalher AM; Lopes AS; Diniz Mde O; Schanoski AS; de Melo RL; Ferreira LC; de Oliveira ML; Demasi M; Ho PL
PLoS One; 2015; 10(9):e0138686. PubMed ID: 26390407
[TBL] [Abstract][Full Text] [Related]
16. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
Yang A; Farmer E; Lin J; Wu TC; Hung CF
Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models.
Veinalde R
Methods Mol Biol; 2020; 2058():213-227. PubMed ID: 31486040
[TBL] [Abstract][Full Text] [Related]
18. Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.
Aitken AS; Roy DG; Martin NT; Sad S; Bell JC; Bourgeois-Daigneault MC
J Immunother; 2018 Apr; 41(3):125-129. PubMed ID: 29293165
[TBL] [Abstract][Full Text] [Related]
19. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
Chandy AG; Nurkkala M; Josefsson A; Eriksson K
Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
